版本:
中国

BRIEF-Amicus Therapeutics says co on track to report top-line data from essence study during Q3

May 19 Amicus Therapeutics Inc

* Says Amicus is on track to report top-line data from essence study during Q3 of 2017

* Amicus Therapeutics announces planned analysis of primary endpoints in Phase 3 epidermolysis bullosa study

* Amicus Therapeutics - completed analysis plan for primary endpoints in blinded Phase 3 clinical study of novel topical medicine SD-101 for epidermolysis bullosa Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐